NYU Langone treats 1,000th focal cryotherapy patient, broadway star André De Shields

André De Shields stepped into a very different kind of cold than the one that dominates wellness feeds. At NYU Langone Health, the Broadway performer became the institution’s 1,000th patient to undergo focal cryotherapy for prostate cancer, a milestone that puts precision freezing at the center of a fast-moving conversation about recovery, function, and survivorship.

NYU Langone marked the June 8 announcement as part of a broader shift in cancer care: not only treating disease, but helping patients get back to daily life with as few long-term side effects as possible. In this case, the treatment is also called focal cryoablation, and it works by using controlled freezing to destroy cancer cells in a targeted part of the prostate while preserving surrounding healthy tissue.

The procedure is done with ultrasound guidance. Physicians insert thin cryoneedles, or cryoprobes, into the prostate and freeze the cancerous area with enough precision to protect nearby structures, including the rectum, bladder, urinary sphincter, erectile nerves, and blood vessels. NYU says that approach can offer an alternative to surgery or radiation for localized cancer, with a lower risk of urinary incontinence and a greatly reduced risk of sexual dysfunction.

De Shields’ quick return helped NYU underscore how minimally invasive the treatment can be for suitable patients. The institution said he was back on stage two days after treatment, a detail that lands hard in a city where the stage is both a workplace and a proving ground.

For readers used to talking about cold plunges, this is where the language splits. The word cryotherapy appears in both worlds, but the overlap ends there. One is a consumer ritual built around cold exposure and recovery culture. The other is a clinical prostate cancer treatment with a targeted workflow, outpatient logic, and a very different safety and evidence base.

NYU Langone said it was one of the earliest pioneers of focal cryotherapy for prostate cancer and has advanced the technique through clinical research and patient outcomes. On its treatment page, the health system says cryotherapy is the most common form of focal therapy it uses, describing controlled freezing and thawing of the prostate gland to destroy cancerous cells in the targeted area. NYU has also said focal therapy was developed at Perlmutter Cancer Center, where a five-year study showed positive results.

The American Cancer Society says cryotherapy and HIFU may be options in certain situations for early-stage prostate cancer, including after radiation therapy, and that some doctors now offer ablative treatments as initial options for some low-risk cases. It also notes that prostate cancer treatment can affect sexual function and can cause bladder or bowel issues after treatment.

That is what makes NYU’s 1,000-patient milestone matter beyond oncology. It shows how far precision freezing has traveled from specialty experiment to mainstream care, and why a word that sounds familiar in ice-bath circles can mean something far more exact in a cancer clinic.